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Abstract: 24 
 
Background: Arbekacin is an aminoglycoside that shows a strong antimicrobial activity 25 
against Gram-positive bacteria, including MRSA as well as Pseudomonas aeruginosa. 26 
The therapeutic effectiveness of arbekacin is directly related to the mean maximum drug 27 
concentration (Cmax) at the infection site. To maximize drug delivery to the respiratory 28 
tract and minimize the systemic toxicity, arbekacin optimized for inhalation, ME1100, is 29 
under development. In this study, we investigated the efficacy and pharmacokinetics of 30 
ME1100 in a murine model of ventilator-associated pneumonia caused by P. aeruginosa 31 
by using customized investigational nebulizer system.  32 
Methods: The mice were treated for 5 minutes, once daily, with placebo, 3, 10, or 30 33 
mg/mL of ME1100 or 30 mg/mL of amikacin.  34 
Results: In the survival study, the survival rate was significantly improved in the 10 and 35 
30 mg/mL ME1100 treatment groups, compared with that in the placebo group. The 36 
number of bacteria in the lungs significantly decreased in the 30 mg/mL ME1100 37 
treatment group at 6 hours after the initial treatment. In the pharmacokinetic study, the 38 
Cmax of the 30 mg/mL ME1100 treatment group in the epithelial lining fluid (ELF) and 39 
plasma was 31.1 μg/mL and 1.2 μg/mL, respectively. Furthermore, we compared the 40 
efficacy of ME1100 with that of amikacin. Although there were no significant differences 41 
in the ELF and plasma concentrations between ME1100 and amikacin, ME1100 42 
significantly improved the survival rate, compared to amikacin.  43 
Conclusions: The results of our study demonstrated the in vivo effectiveness of ME1100 44 
and its superiority to amikacin. 45 
  46 
 
Introduction: 47 
 Arbekacin is an aminoglycoside, which induces cell membrane damage and binds to 48 
both the 50S and 30S ribosomal subunits, resulting in codon misreading and inhibition of 49 
translation.1 It shows a strong antimicrobial activity against Gram-positive bacteria, 50 
including MRSA. The antimicrobial activity of arbekacin against MRSA was equivalent 51 
to that of vancomycin.1,2,3,4 Additionally, arbekacin shows a good antimicrobial activity 52 
against Gram-negative bacteria including Pseudomonas aerunigosa.2,5 Since S. aureus 53 
and P. aeruginosa are the most causative pathogens of HAP including ventilator-54 
associated pneumonia (VAP),5,6 arbekacin might be useful for the treatment of patients 55 
with these diseases. 56 
 The therapeutic effectiveness of arbekacin is directly related to the fraction of the mean 57 
maximum drug concentration (Cmax) at the infection site. The ratio of the Cmax of 58 
arbekacin in the epithelial lining fluid (ELF) to that in the serum is 0.40.7 This data 59 
suggested that a higher dose is needed to treat patients with pneumonia than that needed 60 
for those with bloodstream infections. However, a higher dose will lead to a higher trough 61 
concentration (Ctrough). It is reported that a high Ctrough of aminoglycosides increases the 62 
incidence of kidney-related adverse drug reactions, and therapeutic drug monitoring 63 
(TDM) is required to maximize the efficacy while minimizing the toxicity of 64 
aminoglycosides.1 In the 1990s, inhalation aminoglycosides, such as tobramycin and 65 
amikacin, were developed to maximize the drug delivery to the respiratory tract and 66 
minimize the toxicity. In this study, we investigated the in vivo efficacy of ME1100, a 67 
novel optimized formulation of arbekacin for inhalation, by using a customized 68 
investigational nebulizer system, and compared its efficacy with that of amikacin.  69 
  70 
 
Materials and methods: 71 
Bacterial strains: 72 
 The strain of Pseudomonas aeruginosa used in this study was PANU3724, a clinical 73 
isolate obtained from the endotracheal tube of a patient at the Nagasaki University 74 
Hospital. The bacteria were stored at -80 °C in a Microbank® bead preservation system 75 
(Pro-Lab Diagnostics, Ontario, CA) until use.  76 
 77 
Antimicrobial agents: 78 
 Amikacin sulphate injection was purchased from Sawai Pharmaceutical Co., Ltd. 79 
(Osaka, Japan). ME1100 inhalation solution and placebo inhalation solution were 80 
supplied by Meiji Seika Pharma Co., Ltd. (Tokyo, Japan). ME1100 is a novel formulation 81 
of arbekacin, which provides high concentration and stability for inhalation (International 82 
Application No. PCT/EP2012/065265). The aqueous liquid pharmaceutical composition 83 
of ME1100 inhalation solution is comprised by arbekacin and chloride ions. By the 84 
composition, the sulfate salt form of the arbekacin, which caused coughing reaction, was 85 
reduced. 86 
 87 
Inhalation exposure system: 88 
 The customized investigational eFlow® rapid nebulizer system was supplied by Pari 89 
Pharma GmbH. The average of the Mass Median Aerodynamic Diameter of the ME1100 90 
droplets generated by the nebulizer system was 3.7 ± 0.1 μm, and approximately 73% of 91 
the droplets were in the size range of 0.5 to 5 μm.8 In this study, we constructed the 92 
original nose-only exposure system. We cut the tip of the 50 mL conical centrifuge tubes, 93 
and held the mice in the tube with a posture to put out their nose from the tip of the tubes. 94 
 
Subsequently, we put the tubes into a sealed container which the flow generated by the 95 
nebulizer system passed through. 96 
 97 
Animals: 98 
 We purchased specific pathogen-free male ICR mice (6 to 7-week-old, 25 to 30 g 99 
bodyweight) from Japan SLC, Inc. (Shizuoka, Japan). The mice were housed in a 100 
pathogen-free environment and received sterile food and water in the Biomedical 101 
Research Center at Nagasaki University.  102 
 103 
Ethics: 104 
 All the experimental protocols used in this study were approved by the Ethics Review 105 
Committee for Animal Experimentation (approval number: 1003310842). 106 
 107 
Antimicrobial susceptibility test: 108 
 We determined the MIC of the antimicrobial agents against the PANU3724 strain by a 109 
micro-dilution method in accordance with the guidelines of the CLSI.9 CLSI 110 
interpretative criteria (M100-S24) were applied for testing the susceptibility of the 111 
PANU3724 strain to the antimicrobial agents.10 112 
 113 
Murine model of VAP: 114 
 Disposable sterile plastic cut-down intravenous catheters with a French gauge of 3-Fr 115 
(Atom Co., Tokyo, Japan) were used for tracheal intubation. The catheters were cut to a 116 
length of 5.0 mm and a few slits were made at the proximal end to prevent their clogging 117 
by oral secretions. The bacteria were cultured overnight on a Muller-Hinton II agar 118 
(Becton Dickinson, Le Pont de Claix, France). Then, they were suspended in sterile saline 119 
 
and  the concentration was adjusted at 2 x 108 cfu/mL, as estimated by turbidimetry 120 
(DensiCHEK™ plus: bioMérieux, Hazelwood, MO). Inoculation was carried out as 121 
described previously.11,12,13,14 Briefly, the tubes were inserted through the vocal cords into 122 
the trachea. Subsequently, P. aeruginosa suspended in saline solution (0.05 mL; 1 x 107 123 
cfu/mouse) was inoculated through the outer sheath of the intravenous catheter. 124 
 125 
Treatment protocol: 126 
 ME1100 and amikacin were diluted with the placebo inhalation solution. Twelve hours 127 
post inoculation, the mice were treated for 5 minutes, once daily, with placebo, 3, 10, or 128 
30 mg/mL of ME1100, or 30 mg/mL of amikacin by using a customized investigational 129 
nebulizer system. In the survival study, the mice were treated for 108 hours post 130 
inoculation and the survival rates were observed for 120 hours post inoculation. 131 
 132 
Bacteriological examinations: 133 
 The mice were sacrificed at 18 hours post inoculation i.e., 6 hours after the initial 134 
treatment, by cervical dislocation. Subsequently, they were dissected under aseptic 135 
conditions to collect the blood via a right ventricular puncture using heparin-coated 136 
syringes, and to remove the lungs. The lungs were suspended in 1 mL of normal saline 137 
and homogenized with a homogenizer (AS One Co., Osaka, Japan). Serial dilutions of 138 
the lungs and blood were quantitatively cultured in Mueller-Hinton II agar plates. After 139 
overnight incubation, we evaluated the number of the visible colonies. The lowest level 140 
of detectable bacterial count was 1 x 102 cfu/mL. 141 
 142 
Collection of blood and bronchoalveolar lavage fluid (BALF) for the pharmacokinetic 143 
studies: 144 
 
 The mice were treated for 5 minutes with 30 mg/mL of ME1100 or 30 mg/mL of 145 
amikacin by using a customized investigational nebulizer system, and were then 146 
sacrificed by cervical dislocation at 5, 30 min, 1, 3, 6, and 12 hours post inhalation. Blood 147 
was collected via a right ventricular puncture using heparin-coated syringes. The 148 
bronchoalveolar lavage fluid (BALF) was also collected. Four mice were used for each 149 
group. The collection of BALF was performed as described previously.15,12 Briefly, the 150 
mice were sacrificed and the chest opened to expose the lungs and trachea. A disposable, 151 
sterile, plastic cut-down catheter was inserted into the trachea. BAL was performed three 152 
times sequentially using 1.0 mL of saline each time. Blood and BALF were centrifuged 153 
and the supernatants were stored at -80 °C until use. 154 
 155 
Pharmacokinetic studies: 156 
 The levels of arbekacin and amikacin in the plasma and BALF were measured using a 157 
LC (LC-10Advp, Shimadzu) coupled with a tandem mass spectrometer (Quattro Ultima 158 
Pt, waters). Dibekacin was used as an internal standard (I.S.). All analytes were 159 
determined via measurement of a derivative formed by their reaction with phenyl 160 
isocyanate in the presence of triethylamine. 161 
 When the value of an assessed parameter of a PK sample was expected to exceed the 162 
upper limit of quantification (ULOQ), the sample was diluted 2-fold (plasma) or 5-fold 163 
(BALF) with blank plasma or BALF. Each plasma or BALF sample (10 μL) was 164 
transferred to a tube, and the standard solution (10 μL) and saline (180 μL) were added 165 
and mixed with a vortex mixer. The mixture (50 μL) was transferred to another tube, 166 
and the internal standard solution (50 μL), acetonitrile containing 0.5 % triethylamine 167 
(50 μL), and acetonitrile containing 0.5 % phenyl isocyanate (50 μL) were added and 168 
 
mixed with the vortex mixer. Then, methanol (400 μL) was added. The mixture was 169 
centrifuged at 9100 ×g for 5 min at 4 °C. The supernatant (30 μL) was injected into 170 
the column of the liquid chromatograph-tandem mass spectrometry system. Arbekacin 171 
and amikacin were chromatographically separated on an analytical column (Inertsil ODS-172 
3, 2.1x50 mm, 5 µm, GL Sciences Inc.) using a gradient of water/formic acid (1000:1, 173 
v/v) – acetonitrile as a mobile phase at 40 °C. The flow rate was set at 0.4 mL/min. The 174 
tandem mass spectrometer was operated in the positive ion mode. Arbekacin was 175 
monitored as the precursor ion at 1149 m/z and the product ion at 367 m/z. Amikacin was 176 
monitored as the precursor ion at 1062 m/z and the product ion at 409 m/z. Dibekacin 177 
(I.S.) was monitored as the precursor ion at 1048 m/z and the product ion at 367 m/z. The 178 
assay was linear over 0.05 to 5 mg/L for arbekacin and amikacin in the mouse plasma 179 
and BALF. The accuracy of the assay method ranged between 88.9 % and 114.2 %. 180 
 Measurement of urea concentration in the plasma and BALF was conducted using urea 181 
assay kit (Biochain Institute, Inc) based on Jung method.16 The samples were diluted 50-182 
fold (plasma) or 10-fold (BALF) with saline. The standard curve showed a linear range 183 
from 0.05 to 1 mg/dL. Arbekacin and amikacin concentrations in the ELF were calculated 184 
using the following equation because the ELF was diluted with saline: Arbekacin (or 185 
Amikacin) in ELF = Arbekacin (or Amikacin) in BALF × Urea in plasma / Urea in 186 
BALF.17 187 
For pharmacokinetic analysis, WinNonlin Professional Ver.6.3 (Pharsight Corporation) 188 
was used. 189 
 190 
Statistical analysis: 191 
 
 We used a statistical software package (StatMate V; ATMS Co., Ltd., Tokyo, Japan) for 192 
all the statistical comparisons. The survival rates were calculated using Kaplan-Meier 193 
method. The survival analysis was performed using the log-rank test and the data was 194 
expressed as the mean ± standard deviation (SD). For the plot of the bacterial count in the 195 
lungs and blood, we depicted the data using the box-and-whisker plot and analysed the 196 
differences between the groups using one-way analysis of variance (ANOVA) followed 197 
by Tukey’s post-hoc test. All the tests of significance were two-tailed. The alpha level for 198 
denoting a statistical significance was set at p < 0.05. 199 
 200 
  201 
 
Results: 202 
MICs of the antimicrobial agents against PANU3724: 203 
 The MICs of arbekacin and amikacin against the bacterial strain, PANU3724, were 4 204 
mg/L and 8 mg/L, respectively. This bacterial strain exhibits resistance to carbapenems 205 
(Table 1). 206 
 207 
Therapeutic effects of the antimicrobial agents on the survival rate: 208 
 In the survival study, the mice were treated according to the prescribed methods for 108 209 
hours post inoculation and the survival rates were observed for 120 hours post inoculation 210 
(n = 7 in each group). As shown in Fig. 1, the survival rates were significantly higher in 211 
the 10 and 30 mg/mL ME1100 treatment groups than in the placebo treatment group (P 212 
< 0.001 for both groups). Additionally, the survival rate in the 30 mg/mL ME1100 213 
treatment group was significantly higher than that in the placebo treatment group (P = 214 
0.022). 215 
 216 
Bacteriological examinations: 217 
 Since some mice in the placebo treatment group died at 24 hours post inoculation in the 218 
survival study, the mice were sacrificed 18 hours post inoculation i.e., 6 hours after the 219 
initial treatment (n = 5 in each group) .  220 
 The bacterial count in the lungs of the mice receiving placebo, 3, 10, and 30 mg/mL of 221 
ME1100 was as follows: 9.34 ± 0.23, 9.20 ± 0.33, 8.86 ± 0.31, and 8.09 ± 0.35 log10 222 
cfu/mL, respectively (Fig. 2A). The bacterial count in the lungs significantly decreased 223 
in the 30 mg/mL ME1100 treatment group, compared to that in all other groups (P < 0.001 224 
versus the placebo and the 3 mg/mLME1100 treatment groups; P < 0.05 versus the 10 225 
mg/mL ME1100 treatment group). 226 
 
 The bacterial count in the blood of the mice receiving placebo, 3, 10, and 30 mg/mL of 227 
ME1100 was as follows: 6.08 ± 0.43, 5.36 ± 0.96, 4.91 ± 0.64, and 4.39 ± 1.47 log10 228 
cfu/mL, respectively (Fig. 2B). The bacterial count in the blood significantly decreased 229 
in the 30 mg/mL ME1100 treatment group, compared to that in all other groups (P < 0.001 230 
versus the placebo and the 3 mg/mLME1100 treatment groups; P < 0.05 versus the 10 231 
mg/mL ME1100 treatment group). 232 
 233 
Comparison of ME1100 and amikacin: 234 
 In the survival study, the mice were treated according to the prescribed methods for 108 235 
hours post inoculation and the survival rates were observed for 120 hours post inoculation 236 
(n = 6 in each group). As shown in Fig. 3A, the survival rates were significantly higher 237 
in the 30 mg/mL ME1100 treatment group than in the placebo and 30 mg/mL amikacin 238 
treatment groups (P < 0.005 versus placebo and P = 0.024 versus amikacin).  239 
 In the bacteriological examination, the mice were sacrificed 18 hours post inoculation 240 
i.e., 6 hours after the initial treatment (n = 5 in each group). The bacterial counts in the 241 
lungs of the mice in the placebo, 30 mg/mL ME1100, and 30 mg/mL amikacin treatment 242 
groups were 10.23 ± 0.24, 9.51 ± 0.27, and 10.20 ± 0.05 log10 cfu/mL, respectively (Fig. 243 
3B). The bacterial count in the lungs significantly decreased in the 30 mg/mL ME1100 244 
treatment group, compared to that in the placebo and amikacin treatment groups (P < 245 
0.001 versus both groups). 246 
 247 
Pharmacokinetics of ME1100 248 
 The mice were treated for 5 minutes with 30 mg/mL of ME1100, and then, ELF and 249 
blood were collected at 5, 30 minutes, 1, 3, 6, and 12 hours post inhalation. The calculated 250 
pharmacokinetic parameters of ME1100 are shown in Fig. 4A and Table 2. The Cmax of 251 
 
ME1100 in the ELF and plasma was 31.1 and 1.2 μg/mL, respectively. The areas under 252 
the concentration-time curve from 0 to infinity (AUC0-inf) of ME1100 in the ELF and 253 
plasma were 67.7 and 2.2 μg.h/mL, respectively. The half-lives (t1/2) of ME1100 in the 254 
ELF and plasma were 2.4 and 4.6 h, respectively. The ELF concentration of ME1100 was 255 
significantly higher than its plasma concentration at 5, 30 minutes, 1 and 3 hours post 256 
inhalation (P = 0.028). 257 
 258 
Comparison of the ELF and blood concentrations of ME1100 and amikacin 259 
 The mice were treated for 5 minutes with 30 mg/mL of ME1100 or amikacin, and then 260 
ELF and blood were collected at 5 minutes and 1 hour post inhalation. The concentration 261 
of ME1100 in the ELF at 5 minutes and 1 hour post inhalation was 31.1 ± 13.6 and 20.2 262 
± 17.6, respectively, and that of amikacin was 46.7 ± 16.1 and 19.1 ± 13.3, respectively 263 
(Fig. 4B). The concentration of ME1100 in the plasma at 5 minutes and 1 hour post 264 
inhalation was 1.2 ± 0.5 and 0.4 ± 0.1, respectively, and that of amikacin was 2.5 ± 1.7 265 
and 0.5 ± 0.2, respectively (Fig. 4C). There was no significant difference between the 266 
ELF and blood concentrations of ME1100 and amikacin. 267 
 268 
  269 
 
Discussion: 270 
 Antimicrobial agents, such as tobramycin, colistin, and aztreonam, have been 271 
administered via inhalation to patients with chronic respiratory tract infections caused by 272 
P. aeruginosa. P. aeruginosa has been a common cause of HAP including VAP.5,6 273 
Although there are several anti-pseudomonal agents, P. aeruginosa is associated with 274 
high in-hospital mortality and prolonged length of stay in hospitals.18 The treatment of P. 275 
aeruginosa infection has been difficult because the bacteria possess numerous 276 
mechanisms of antimicrobial resistance. Therefore, there is a need to develop novel 277 
antimicrobial agents effective against P. aeruginosa. In the ATS / IDSA guidelines, 278 
combination therapy with aminoglycosides and beta-lactams was recommended as an 279 
empiric treatment for patients with VAP caused by drug-resistant Gram-negative bacteria 280 
including P. aeruginosa.19 However, this combination therapy for sepsis was discouraged 281 
due to the significant risk of nephrotoxicity.20 To decrease the risk of nephrotoxicity, some 282 
aminoglycosides formulations were optimized in order to be administered via inhalation 283 
in patients with VAP.21 In this study, ME1100, optimized for inhalation, showed a good 284 
in-vivo antimicrobial activity in a murine model of VAP caused by P. aeruginosa. In the 285 
survival study, ME1100 treatment (30 mg/mL) significantly improved the survival rate in 286 
comparison with the placebo group, in which the infected mice died within 48 hours post 287 
inoculation. In addition, ME1100 (30 mg/mL) significantly reduced the bacterial count in 288 
the lungs and blood when administered only once. 289 
 The primary purpose of the inhalation route is to maximize the drug delivery to the target 290 
site of infection and limit the potential for systemic side effects. Arbekacin, a 291 
conventional formulation of ME1100, is classified as a kanamycin aminoglycoside. The 292 
therapeutic effectiveness of aminoglycosides is directly related to the Cmax, and the 293 
previous study reported that the probability of cure/improvement was risen when the Cmax 294 
 
of arbekacin was increased.22 In patients with pneumonia, the local concentration of the 295 
antimicrobial agents at the infection site, such as ELF, is important.23 A previous study on 296 
the intravenous administration of arbekacin reported that the ratio of the Cmax of arbekacin 297 
in the ELF to that in the serum is 0.40.7 These data suggested that a higher dose of 298 
arbekacin would be needed to treat patients with pneumonia via intravenous 299 
administration rather than via inhalation. In this study, the ratio of the Cmax of ME1100 in 300 
the ELF to that in the plasma was approximately 25.9. Accordingly, ME1100 could 301 
contribute to the treatment of patients with VAP by maximizing the drug delivery to the 302 
respiratory tract. However, there is a possibility of the resistance emergence in the patients 303 
with bacteremia because the low Cmax of ME1100 in the plasma would facilitate the drug-304 
resistance. Therefore, as described in the ATS / IDSA guidelines19, the combination of 305 
ME1100 and beta-lactams might be recommended in clinical use. 306 
 Among the aminoglycosides optimized for inhalation, amikacin is frequently reported. 307 
Several clinical studies reported that administration of amikacin via inhalation is effective 308 
in patients with VAP.24,25,26 In this study, we compared the in vivo efficacy and 309 
pharmacokinetics of ME1100 with that of amikacin. Although there were no significant 310 
differences in the drug concentrations in the ELF and plasma between ME1100 and 311 
amikacin, ME1100 significantly improved the survival rate, compared to amikacin. 312 
However, the nebulizer system used in this study was customized for inhalation of 313 
ME1100. Additionally, we did not adjust the doses of ME1100 and amikacin based on 314 
their pharmacokinetics. The MIC of amikacin against PANU3724 strain is higher than 315 
that of ME1100, and the calculated Cmax / MIC of amikacin was lower than that of 316 
ME1100 (5.8 for amikacin and 7.8 for ME1100, respectively). Since the optimized 317 
formulation of amikacin for inhalation, known as BAY41-6551 or NKTR-061 is under 318 
development24, it is necessary to compare ME1100 and the optimized amikacin 319 
 
formulation for inhalation in the future.  320 
 Some previous studies reported that arbekacin shows a strong antimicrobial activity 321 
against Gram-positive bacteria including MRSA.3,4 Since arbekacin is stable to the 322 
aminoglycoside-inactivating enzymes produced by MRSA, it shows the most potent 323 
antimicrobial activity against MRSA among the aminoglycosides.1 Additionally, the MIC 324 
required to inhibit the growth of 90% of organisms (MIC90) of arbekacin against MRSA 325 
is 0.5 μg/mL, which is lower than that of vancomycin and linezolid (1 and 2 μg/mL, 326 
respectively).1 Since P. aeruginosa and S. aureus, including MRSA are the most and the 327 
second most frequent isolated pathogens from patients with VAP,5 ME1100 might be 328 
useful for the treatment of patients with VAP. 329 
 There were some limitations in this study. First, we used only one clinical strain of P. 330 
aeruginosa and one mouse species in this study. Second, it is very difficult to predict the 331 
efficacy of ME1100 in human because ME1100 is still under development and the 332 
pharmacokinetics of ME1100 in human remains unknown. Third, in this study, the 333 
amikacin sulphate injection used, was not optimized for inhalation. Finally, we did not 334 
investigate the toxicity of ME1100 and amikacin in this study. 335 
 In conclusion, the results of our study demonstrated the in vivo effectiveness of ME1100 336 
and its superiority to amikacin. Further investigations, including clinical trials, are needed 337 
to determine the efficacy of ME1100 in patients with VAP. 338 
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Table 2. Selected pharmacokinetic parameters estimated for ME1100 in ELF and plasma 
 Cmax tmax t1/2 AUC0-inf 
 (μg/mL) (h) (h) μg h/mL 
ELF 31.1 0.08 2.4 67.8 
Plasma 1.2 0.08 4.6 2.9 
Cmax, maximum drug concentration; tmax, time to maximum concentration; t1/2, half-life; AUC0-inf, area 
under the concentration-time curve from 0 to infinity. 
 437 
 438 
  439 
Table 1. The MICs of antimicrobial agents against the PANU3724 
 PIPC/TAZ CAZ AZT IPM MEPM DRPM GM AMK ME1100 CPFX 
MIC (g/L) 32 8 16 32 16 8 4 8 4 1 
Susceptibility a I S I R R R S S NA S 
The susceptibility of 10 antimicrobial agents against PANU3724 was determined. PIPC/TAZ, piperacillin – tazobactam (PIPC : TAZ 
= 8 : 1); CAZ, ceftadizime; AZT, aztreonam; IPM, imipenem; MEPM, meropenem; DRPM, doripenem; GM, gentamicin; AMK, 
amikacin; ME1100, arbekacin ihalation solution; CPFX, ciprofloxacin. 












Figure legends: 446 
Fig. 1. Therapeutic effects of ME1100 on the survival rate.  447 
 Twelve hours post inoculation, the mice were treated for 5 minutes, once daily, with 448 
placebo, 3, 10, or 30 mg/mL of ME1100. Survival was estimated at the indicated time, 449 
and the results are displayed as a Kaplan-Meier plot. The black triangles represent the 450 
time of treatment. The survival rates were observed for 120 hours after inoculation (n = 451 
7 in each group). * The survival rates in the 30 mg/mL ME1100 treatment group was 452 
significantly higher than that in the placebo and 3 mg/mLME1100 treatment groups (P < 453 
0.001 versus placebo, and P = 0.022 versus the 3 mg/ mL of ME1100).† The survival rates 454 
in the 10 mg/mL ME1100 treatment group were significantly higher than those in the 455 
placebo group (P < 0.001). 456 
 457 
Fig. 2. Bacterial count in the lungs and blood.  458 
 Twelve hours post inoculation, the mice were treated for 5 minutes with placebo, 3, 10, 459 
or 30 mg/mL of ME1100. Six hours after the initial treatment, the mice were sacrificed, 460 
and the number of bacteria in the lungs (A) and the blood (B) was analysed (n = 5 in each 461 
groups). Box-and-whisker plots showing the range and median of the bacterial count. The 462 
bacterial count in the lungs was significantly decreased in the 30 mg/mL ME1100 463 
treatment group, compared with all other groups (* P < 0.001 versus the placebo and 3 464 
mg/mL ME1100; † P < 0.05, versus the 10 mg/mL of ME1100). The bacterial count in 465 
the blood of the mice treated with 30 mg/mL of ME1100 was significantly decreased in 466 
comparison with the placebo group († P < 0.05). 467 
 468 
Fig. 3. Comparison of ME1100 and amikacin.  469 
 
 Twelve hours post inoculation, the mice were treated for 5 minutes, once daily, with  470 
placebo, 30 mg/mL of ME1100, or 30 mg/ml of amikacin. Survival was estimated at the 471 
indicated time, and the results are displayed as a Kaplan-Meier plot (A). The black 472 
triangles represent the time of treatment. The survival rates were observed for 120 hours 473 
after inoculation (n = 6 in each group). *The survival rates in the ME1100 treatment group 474 
was significantly higher than that in the placebo and the 30 mg/mL of amikacin treatment 475 
groups (P < 0.005, versus placebo and P = 0.024, versus amikacin).  476 
 Six hours after initial treatment, the mice were sacrificed, and the number of bacteria in 477 
the lungs was analysed (n =5 in each groups). Box-and-whisker plots showing the range 478 
and median of the number of bacteria (B). The number of bacteria in the lungs was 479 
significantly decreased in the ME1100 treatment group, compared with the placebo and 480 
amikacin treatment groups (†P < 0.001 versus both groups). 481 
 482 
Fig. 4. ELF and plasma concentrations of ME1100 and amikacin 483 
 The mice were treated for 5 minutes with placebo, 30 mg/mL of ME1100, or amikacin 484 
(n = 4 in each group). The pharmacokinetics of ME1100 in ELF (filled black rhombus) 485 
and plasma (filled gray square) were measured at 5, 30 minutes, 1, 3, 6, and 12 hours post 486 
inhalation (A). *The concentration of ME1100 in the ELF was significantly higher than 487 
that in the plasma for 3 hours post inhalation (P = 0.028). The concentrations of ME1100 488 
and amikacin in ELF (B) and plasma (C) were compared at 5 minutes and 1 hour post 489 
inhalation. There were no significant differences between ME1100 and amikacin 490 
concentrations in both ELF and plasma. 491 
 492 
